arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Kodiak Sciences Inc.

KOD
$45.31 ▼ -0.09 (-0.19%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
37 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Kodiak Sciences Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.8B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -42.1%
FCF / Share $-0.66
Trailing P/E
Price / Book 25.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

37-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-58.16M
↓ -1.2%
FCF / Share Free cash flow per share
$-0.66
↓ -19.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
5
Cash Quality
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 37 quarters